Tonya Martin

ORCID: 0009-0001-9756-3445
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatic function and diabetes
  • Diabetes Treatment and Management
  • Metabolism, Diabetes, and Cancer
  • Innovations in Medical Education
  • Diet and metabolism studies
  • Diabetes Management and Research
  • Evaluation of Teaching Practices
  • Autoimmune and Inflammatory Disorders Research
  • Rheumatoid Arthritis Research and Therapies
  • Liver Disease Diagnosis and Treatment
  • Reflective Practices in Education
  • Redox biology and oxidative stress
  • Receptor Mechanisms and Signaling
  • Amino Acid Enzymes and Metabolism
  • Pregnancy and Medication Impact
  • Chronic Lymphocytic Leukemia Research
  • Global Health Workforce Issues
  • Diabetes and associated disorders
  • Pharmacology and Obesity Treatment
  • Pharmacological Effects and Toxicity Studies
  • Maternal and fetal healthcare
  • Nursing education and management
  • Muscle and Compartmental Disorders
  • Biochemical effects in animals
  • Blood Pressure and Hypertension Studies

Florida Agricultural and Mechanical University
2015-2023

Janssen (United States)
2014-2022

Baylor Medical Center at Garland
2022

Springhouse
2014-2018

Johnson & Johnson (United States)
2009-2014

Background Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of type diabetes mellitus (T2DM). Methods 14C-alpha-methylglucoside uptake Chinese hamster ovary-K cells expressing human, rat, or mouse SGLT2 SGLT1; 3H-2-deoxy-d-glucose L6 myoblasts; and 2-electrode voltage clamp recording oocytes human SGLT3 were analyzed. Graded infusions performed to determine rate urinary excretion (UGE) at different blood (BG) concentrations renal...

10.1371/journal.pone.0030555 article EN cc-by PLoS ONE 2012-02-15

GPR40 is a G-protein-coupled receptor which mediates fatty acid-induced glucose-stimulated insulin secretion from pancreatic beta cells and incretion release enteroendocrine of the small intestine. full agonists exhibit superior glucose lowering compared to partial in preclinical species due increased GLP-1 secretion, with added benefit promoting weight loss. In our search for potent agonists, we discovered superagonist displayed excellent vitro potency efficacy Gαs-mediated signaling...

10.1021/acsmedchemlett.8b00444 article EN ACS Medicinal Chemistry Letters 2018-12-03

Diabetes is a high risk factor for dementia. High glucose may be dementia even among persons without diabetes, and in transgenic animals it has been shown to cause potentiation of indices that are pre-symptomatic Alzheimer′s disease. To further elucidate the underlying mechanisms linking inflammatory events elicited brain during oxidative stress we monitored activation mitogen-activated kinsase (MAPKs), c-jun NH2-terminal kinase (JNK), p38 MAP kinases (p38MAPK), extracellular activating...

10.1016/j.redox.2013.12.018 article EN cc-by Redox Biology 2014-01-01

The free fatty acid receptor 1 (FFAR1/GPR40) mediates acid-induced insulin secretion from pancreatic β-cells. At least 3 distinct binding sites exist on the FFAR1 and numerous synthetic ligands have been investigated for their anti-diabetic actions. Fasiglifam, binds to site-1 stimulates intra-cellular calcium release improves glycemic control in diabetic patients. Recently, small molecule agonists were discovered which bind site-3, stimulating both cAMP, resulting glucagon-like peptide-1...

10.3389/fendo.2022.1061688 article EN cc-by Frontiers in Endocrinology 2022-11-22

Purpose This study describes how an employer-based tuition-assistance program for homecare workers at one Canadian organization enabled nursing career advancement and retention.

10.1080/07370016.2024.2314077 article EN Journal of Community Health Nursing 2024-02-23

The free fatty acid receptor 1 (FFAR1) mediates acid-induced insulin secretion from pancreatic β-cells. Numerous ligands have been investigated for their antidiabetic actions. most advanced, fasiglifam (TAK-875), is a site binding agonist that stimulates IPone and improves glycemic control in diabetic patients via glucose-dependent (GSIS). Recently, FFAR1 agonists were discovered bind to 3, stimulate cAMP result both glucagon-like peptide-1 (GLP-1) secretion. We hypothesized this novel...

10.2337/db18-609-p article EN Diabetes 2018-06-22

In rheumatoid arthritis, the use of Routine Assessment Patient Index Data 3 (RAPID3) assessments to meet treat-to-target goals is endorsed by 2021 American College Rheumatology guidelines. November 2020, Baylor Scott & White specialty pharmacy implemented a new service that included more frequent collection RAPID3 scores and standardized provider communication for patients co-managed rheumatology clinic. The objective was evaluate impact this on arthritis disease activity. Before started,...

10.1080/08998280.2022.2139955 article EN Baylor University Medical Center Proceedings 2022-11-09
Coming Soon ...